Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: ghettogoulash who wrote (45888)	4/24/2018 8:53:46 AM
From: Fitzhughlaw	12 Recommendations Read Replies (2) of 63283

The CL2A linker that is used in SG to bind the antibody (hRS7) to the toxic payload (SN-38) was developed using the Dock-And-Lock technology. The linker has enormous value in my opinion, because it keeps the SN-38 inactive while it's circulating in the bloodstream and on the way to the tumor, and its potential for future uses is manifest. Thus, years after it was announced in 2006 (I believe, but am working from memory) with great fanfare, but obtaining a collective yawn from the capital markets, DNL has apparently delivered great shareholder value. MAF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next